Canada Periodontal Therapeutics Market Analysis

Canada Periodontal Therapeutics Market Executive Summary

Canada Periodontal Therapeutics Market is at around $69.8 Mn in 2023 and is projected to reach $113.6 Mn in 2030, exhibiting a CAGR of 7.2% during the forecast period.

Gum disease, sometimes referred to as periodontal disease, is a serious dental condition that is linked to infection and inflammation of the gums that surround teeth. A frequent ailment that is typically brought on by poor oral hygiene is periodontitis, which is mostly preventable with the use of therapeutic, non-surgical, or surgical treatment methods. Periodontal therapeutics, a relatively new yet profitable approach that is gaining favour with patients and dentists, comprises treating periodontitis with antibiotics alone. In periodontal therapy, metronidazole, amoxicillin, and doxycycline are often utilized antibiotics. A range of mouthwashes and rinses with antimicrobial ingredients such as hydrogen peroxide, chlorhexidine, and essential oils are adjunctive therapies for lowering gingival inflammation and plaque.

In Canada, 41% of adults with teeth have or have had, a moderate or severe periodontal problem. Demographically, it shows higher incidence rates in older adults. Healthcare expenses associated with treating periodontitis contribute substantially to Canada's dental care costs, influenced by treatments ranging from non-surgical interventions to surgical procedures. The market reflects ongoing efforts in public health and dentistry to manage and reduce the disease burden through preventive measures and effective treatments, highlighting the importance of oral hygiene and regular dental care in mitigating its prevalence and associated costs. Therefore, the market is driven by significant factors like Prevalence of periodontitis, Rise in Demand for Non-surgical Periodontal Therapies, and Emphasis on Preventive Oral Care. However, Regulatory Complications, Adverse Effects, and High Cost restrict the growth and potential of the market.

AMD Lasers announced the development of the Monet™ laser curing light, the first handheld laser in curing light for dental materials.

Market Dynamics

Market Growth Drivers

Prevalence of periodontitis: The periodontal market thrives on widespread disease prevalence. 41% of the population is still affected by periodontal disease.  This health crisis fuels a robust industry of treatments, tools, and preventive products. As awareness grows and risk factors persist, the market sees continued investment and innovation, contributing significantly to the overall dental economy. The situation is worsened by increasing urbanization and changing lifestyles, contributing to a rise in oral health issues.

Rise in Demand for Non-surgical Periodontal Therapies: Demand for non-surgical treatments for periodontal diseases has increased significantly in the past few years. The treatments include periodontal scaling & root planning and usage of antibiotics, especially in severe forms of periodontal disease. Advances in pharmacologic therapies are expected to create significant opportunities for companies in the market in the next few years.

Emphasis on Preventive Oral Care: Dental practitioners emphasize preventive care, patient education, and early intervention in periodontal health management. Regular check-ups, screenings, and tailored care plans are crucial for mitigating disease progression. Professionals advocate for comprehensive approaches, including maintenance therapies, hygiene instructions, and prophylaxis services. The focus on patient-centered care ensures that treatment plans are customized to meet specific needs, promoting long-term periodontal health and overall well-being.

Market Restraints

Regulatory Complications: Canada, stringent regulatory approval processes for new periodontal treatments and technologies significantly delay market entry, hampering innovation uptake. High compliance costs and rigorous clinical trial requirements further burden market players, limiting affordability and accessibility for patients.

Adverse Effects: In Canada, one significant restraint on the periodontal market is the potential for adverse side effects from treatments such as scaling and root planing, which can include tooth sensitivity and gum irritation. These side effects may deter patients from seeking or completing necessary treatments, impacting market demand.

High cost: With dental care not fully covered by the national healthcare system, many Canadians face out-of-pocket expenses that can be prohibitive. Advanced periodontal procedures, such as dental implants and regenerative surgeries, often exceed the financial reach of average citizens, discouraging timely treatment and leading to deteriorating oral health. According to a report by the Canadian Dental Association, over 32% of Canadians do not have dental insurance, exacerbating this issue.

Regulatory Landscape and Reimbursement scenario

Periodontics market is governed by stringent regulatory frameworks aimed at ensuring patient safety and treatment efficacy. Regulations set by Health Canada and provincial dental regulatory bodies oversee aspects such as practitioner qualifications, treatment standards, and the use of dental materials. These guidelines dictate licensing requirements for periodontists, sterilization protocols for instruments, and the approval process for new treatment methodologies or technologies. Compliance with these regulations is essential for practitioners and industry stakeholders to maintain high standards of care and uphold patient trust in the dental periodontics market across Canada.

Dental insurance plans typically cover periodontal treatments to varying extents, influenced by deductibles, co-payments, and annual maximums. Direct billing by practitioners to insurance companies is common, ensuring patients receive timely reimbursements. Fee schedules and coverage policies differ among insurers, impacting treatment decisions and patient outcomes. Understanding these reimbursement dynamics is crucial for periodontists, shaping treatment planning and patient affordability while navigating the complexities of insurance guidelines. Clear communication between practitioners, insurers, and patients is essential to optimize care delivery and financial transparency in Canada's periodontics landscape.

Competitive Landscape

Key Players

Here are some of the major key players in Canada Periodontal Therapeutics Market:

• Pfizer Inc.
• Lupin Ltd
• Teva Pharmaceuticals USA, Inc.
• Sun Pharmaceutical Industries Ltd.
• Tokyo Chemical Industry Co., Ltd.
• Bausch Health Companies Inc.
• Melinta Therapeutics LLC
• Cipla, Inc.
• Chartwell Pharmaceuticals LLC.
• ASA Dental S.p.A.
• Steris-Hu-Friedy
• Carl Martin GmBH